Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MannKind Corporation (MNKD) News: FDA Approval, Cloud Hosting & More

Editor’s Note: Related tickers: MannKind Corporation (NASDAQ:MNKD), Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

MannKind Corporation (NASDAQ:MNKD)MannKind Nears End of Clinical Trial, Medical Breakthrough (SignalSCV)
With luck, Santa Clarita’s MannKind Corporation (NASDAQ:MNKD) hopes to have FDA approval by April of next year of its innovative diabetes treatment – Afrezza. First conceived in 2011, and funded to a great extent by serial biomed and high tech entrepreneur Alfred Mann, MannKind Corporation (NASDAQ:MNKD) is a publically traded company whose shares of stock have risen steadily as the company approached the end of its final clinical trials on June 17. Treating diabetes with insulin, a very potent drug, is tricky, said Matthew Pfeffer, corporate vice president and CFO of the MannKind Corporation (NASDAQ:MNKD).

NASDAQ Active Stock Watch List: MannKind Corp. (NASDAQ:MNKD) and Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Added to Equity Profile Report’s NASDAQ Active Stock Watch List. (SBWire)
Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding MannKind Corporation (NASDAQ:MNKD) and Synta Pharmaceuticals Corp. (NASDAQ:SNTA). MannKind Corporation (NASDAQ:MNKD) a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States is currently down (-1.07%) on 2,129,210 shares traded. MannKind Corporation (NASDAQ:MNKD) is currently down (-8.93%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

MannKind Corporation Implements BioPharm Systems’ Siebel Clinical Trial Management System Accelerator to Support Growing Product Pipeline (Virtual-Strategy)
MannKind Corporation (NASDAQ:MNKD) has implemented BioPharm Systems’ ASCEND, a pre-configured and enhanced version of Oracle’s Siebel Clinical Trial Management System (CTMS), to support its growing biopharmaceutical product pipeline. ASCEND is replacing MannKind Corporation (NASDAQ:MNKD)’s existing commercial CTMS, which no longer meets the needs of their clinical operations team. In addition to choosing ASCEND, MannKind Corporation (NASDAQ:MNKD) also elected to leverage BioPharm’s cloud hosting platform and managed services in order to reduce costs and save time.

Major Declaration from Biotech Stocks (FiscalInsider)
Biotech apprehension MannKind Corporation (NASDAQ:MNKD) has seen its shares almost triple in value over the previous year, with investors confident that its gulped insulin product Afrezza will obtain FDA authorization soon. The stock has huge prospects, although it has also significant risk, with authorization and strong sales not yet in place. In addition, a lot of success is already built into the stock’s current price, send-off less upside.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.